ERYTECH Pharma completes the enrollment of patients in its Phase I clinical trial in pancreatic cancer Post author:admERY Post published:June 27, 2011 Post category:Newsroom ERYTECH Pharma has just completed the enrollment of patients in a Phase I clinical trial with its flagship product for pancreatic cancer, Graspa®. You Might Also Like ERYTECH Provides Business Update and Reports Financial Results for First Quarter 2019 May 6, 2019 ERYTECH reçoit la désignation Fast Track de la FDA américaine pour eryaspase dans le traitement de la LAL hypersensible July 29, 2021 ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer April 20, 2020
ERYTECH reçoit la désignation Fast Track de la FDA américaine pour eryaspase dans le traitement de la LAL hypersensible July 29, 2021
ERYTECH Provides Update on the TRYbeCA-1 Phase 3 Clinical Trial of Eryaspase in Second Line Pancreatic Cancer April 20, 2020